An update on the use of lenalidomide for the treatment of multiple myeloma
Article 2015 en
Authors
FZ
Flora Zagouri
ET
Evangelos Terpos
EK
Efstathios Kastritis
Abstract
1 min read
Lenalidomide combined with dexamethasone is a safe and effective option for newly diagnosed MM patients ineligible for autologous stem cell transplantation (ASCT). Long-term administration of the agent as continuous treatment for ineligible for ASCT patients or maintenance therapy after ASCT has documented unprecedented progression-free survival improvements, whereas lenalidomide in combination with dexamethasone has shown deep and durable remissions for patients with relapsed and/or refractory disease.
Monika Engelhardt, Evangelos Terpos, Martina Kleber, Francesca Gay, Ralph Wäsch, Gareth J. Morgan, Michèle Cavo, Niels W.C.J. van de Donk, Andreas Beilhack, Benedetto Bruno, Hans Erik Johnsen, Roman Hájek, Christoph Driessen, Heinz Ludwig, Meral Beksaç, Mario Boccadoro, Christian Straka, S. Brighen, Martin Gramatzki, Alessandra Larocca, H M Lokhorst, Valeria Magarotto, Fortunato Morabito, Meletios A Dimopoulos, Hermann Einsele, Pieter Sonneveld, Antonio Palumbo
Katja Weisel, Chantal Doyen, Meletios A Dimopoulos, Adrian Yee, Juan José Lahuerta, Amber Martin, Karin Travers, Eric Druyts, Kabirraaj Toor, Niels Abildgaard, Jin Lu, Jan Van Droogenbroeck, Catarina Geraldes, Mario Petrini, Laurent Voillat, Éric Voog, Thierry Façon
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michèle Cavo, Antonio Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand,
Discussion(0)
No comments yet. Be the first to comment.